Megan Beatty, MD
Obstetrics/Gynecology · Dublin
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 20 years
- Graduated 2006
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Beatty’s office at (925) 875-6100 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A101174 · Current
Licensed to practise in California · since 2007 · expires 2026-12-31 · Drexel University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$5,918
Medicare paid this office $5,918 for 54 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 15 | $1,369 | $68 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 24 | $1,142 | $48 |
Who their Medicare patients are
54 Original Medicare patients in 2024. Average age 74 · Women 100% · Health risk score 0.71. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 52%.
The office billed $24,271, Medicare allowed $8,223 and paid $5,918; for 78 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 54 | 78 | 74 | 0.71 | $24,271 | $5,918 |
| 2023 | 74 | 120 | 74 | 0.73 | $41,201 | $11,011 |
| 2022 | 78 | 123 | 71 | 0.75 | $33,701 | $9,057 |
| 2021 | 75 | 115 | 72 | 0.96 | $28,590 | $8,528 |
| 2020 | 46 | 73 | 69 | 0.63 | $16,188 | $4,387 |
| 2019 | 60 | 106 | 72 | 1.04 | $28,042 | $6,484 |
| 2018 | 52 | 239 | 69 | 0.97 | $21,877 | $5,178 |
| 2017 | 59 | 99 | 69 | 0.86 | $23,436 | $5,643 |
| 2016 | 49 | 96 | 69 | 1.13 | $28,271 | $6,809 |
| 2015 | 53 | 114 | 71 | 1.16 | $41,789 | $10,606 |
| 2014 | 52 | 120 | 72 | 1.17 | $40,797 | $9,861 |
| 2013 | 45 | 95 | 71 | 1.21 | $26,505 | $6,846 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Short return visit (20+ min) | 21 | $2,629 | $73 |
| Return visit (30+ min) | 18 | $2,383 | $108 |
| New patient visit (45+ min) | 11 | $1,638 | $149 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $1,008 | $48 |
2022: 3 services
| Return visit (30+ min) | 18 | $1,925 | $101 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 40 | $1,886 | $47 |
| Short return visit (20+ min) | 15 | $1,866 | $69 |
2021: 3 services
| Return visit (30+ min) | 17 | $2,391 | $120 |
| Short return visit (20+ min) | 19 | $2,076 | $74 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 30 | $1,428 | $48 |
2020: 2 services
| Short return visit (20+ min) | 21 | $1,818 | $55 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 13 | $625 | $48 |
2019: 2 services
| Short return visit (20+ min) | 25 | $2,806 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 25 | $1,169 | $47 |
2018: 3 services
| Short return visit (20+ min) | 24 | $2,342 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 16 | $719 | $45 |
| New patient visit (15+ min) | 12 | $636 | $53 |
2017: 2 services
| Short return visit (20+ min) | 28 | $2,538 | $58 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 19 | $846 | $45 |
2016: 2 services
| Short return visit (20+ min) | 28 | $2,938 | $59 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 12 | $518 | $43 |
2015: 2 services
| Short return visit (20+ min) | 27 | $2,715 | $60 |
| New patient visit (15+ min) | 12 | $755 | $63 |
2014: 3 services
| Short return visit (20+ min) | 23 | $2,190 | $55 |
| Return visit (30+ min) | 11 | $1,048 | $81 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 11 | $471 | $43 |
2013: 3 services
| Return visit (30+ min) | 13 | $1,618 | $85 |
| Short return visit (20+ min) | 11 | $1,107 | $62 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 17 | $736 | $43 |
Drugs they prescribed that Part D paid
$16,211
Pharmacies billed $16,211 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 145) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
115 generic and 30 brand-name prescriptions · $16,211 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 32 | $2,127 | $66 |
| Yuvafem | 16 | $1,758 | $110 |
Year by year
| 2024 | 145 | 53 | 0% (0) | 21% | $16,211 |
| 2023 | 149 | 52 | 0% (0) | None | $21,867 |
| 2022 | 133 | 42 | 0% (0) | 18% | $20,925 |
| 2021 | 140 | 44 | 0% (0) | 13% | $24,223 |
| 2020 | 98 | 27 | 0% (0) | 12% | $12,497 |
| 2019 | 70 | 26 | 0% (0) | 19% | $10,741 |
| 2018 | 80 | 28 | 0% (0) | 26% | $11,442 |
| 2017 | 100 | 36 | 0% (0) | 33% | $17,560 |
| 2016 | 102 | 30 | None | 40% | $14,606 |
| 2015 | 89 | 22 | None | None | $14,455 |
| 2014 | 110 | 25 | None | 41% | $12,865 |
| 2013 | 95 | 24 | None | 48% | $10,968 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Estradiol | 41 | $5,261 | $128 |
| Yuvafem | 19 | $2,751 | $145 |
| Valacyclovir | 14 | $1,079 | $77 |
2022: 2 drugs
| Yuvafem | 20 | $3,122 | $156 |
| Estradiol | 27 | $2,343 | $87 |
2021: 2 drugs
| Yuvafem | 16 | $3,430 | $214 |
| Estradiol | 34 | $3,293 | $97 |
2020: 1 drug
| Estradiol | 18 | $1,622 | $90 |
2019: 1 drug
| Estradiol | 15 | $1,510 | $101 |
2018: 1 drug
| Estradiol | 18 | $2,063 | $115 |
2017: 3 drugs
| Premarin | 21 | $6,434 | $306 |
| Estrace | 16 | $5,866 | $367 |
| Estradiol | 12 | $2,079 | $173 |
2016: 3 drugs
| Estrace | 13 | $4,118 | $317 |
| Premarin | 12 | $2,997 | $250 |
| Estradiol | 16 | $878 | $55 |
2015: 1 drug
| Mimvey | 11 | $1,188 | $108 |
2014: 3 drugs
| Premarin | 16 | $3,772 | $236 |
| Vesicare | 13 | $2,896 | $223 |
| Fluconazole | 14 | $124 | $9 |
2013: 2 drugs
| Oxybutynin Chloride Er | 11 | $1,321 | $120 |
| Estradiol | 11 | $561 | $51 |
Money from drug and device companies
$25 in 2023
A payment is not proof that care is biased.
| CooperSurgical | Summit Doppler | $25 | 1 payment
|
See the published payment
| CooperSurgical | Consulting · 2023-05-11 | Summit Doppler | $25 |
Professional record
- NPI
- 1518141142
- Licence
- CA A101174California A101174: Current · expires 2026-12-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-12-18
- NPI last updated
- 2025-10-23
- NPI record certified
- 2025-10-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 20103 Lake Chabot Rd, Castro Valley, CA, 94546